Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Efficacy of secukinumab as first-line bDMARD vs standard-of-care
RMDs: Experts tell you what to expect in 2025
JOURNALS
Start Learning
RMDs: What to Expect in 2025
Luis Felipe Ensina, leading innovation in allergy and immunology
JOURNALS
Start Learning
Global Impact, Brazilian Roots: Prof. Ensina’s Journey Leading Innovation in Allergy and Immunology
JOURNALS
Start Learning
Optimizing Tumour Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis: Embracing Personalized Medicine
JOURNALS
Start Learning
Honouring Prof. Marcus Maurer
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
JOURNALS
Start Learning
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
RheumaPreg 2025 Vinod Ravindran International Conference on Reproduction, Pregnancy and Rheumatic Diseases
JOURNALS
Start Learning
Dr Vinod Ravindran joins touchREVIEWS in RMD Editorial Board – Bringing a Wealth of Knowledge in Clinical Rheumatology
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis

to view Favourites, Keep Notes and Track CME Credits

Favourites
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
View
Breakthrough treatments for hereditary angioedema revealed at EAACI 2024
View
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
View
Study finds comparable cardiovascular risk between JAKi and anti-TNFs in IBD
View
Clinical Phenotyping and Molecular Endotyping in Osteoarthritis – Personalised Approaches to Therapeutics: Ali Mobasheri, WCO-IOF-ESCEO 2025
View
B-cell depleting agent reduces risk of flares and increases chance of remission in IgG4-RD
View
Advancing Osteoarthritis Research Through Immunology and Clinical Insight: An Interview with Future Leader, Dr Tom Appleton
View
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
View
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
View
Medics For Rare Disease – New Year, New Strategy
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup